Journal of Clinical Trials
Open Access

Department of Cardiology, Nihon UniversityHospital, Tokyo, Japan

Biography

Naoya Matsumoto is at Nihon University in Tokyo, Japan. Dr. Matsumoto is highly rated in 10 conditions, according to our data. His top areas of expertise are Coronary Heart Disease, Unstable Angina, Angina, and Atherosclerosis.His clinical research consists of co-authoring 195 peer reviewed articles in the past 15 years.

Publications

• Research Article   
  Design and Rational for a Prospective Randomized Study of Safety Outcomes Treated with Edoxaban in Patients with Stable Coronary Artery Disease and Atrial Fibrillation (PRAEDO AF Study)
  Author(s): Daisuke Fukamachi, Yasuo Okumura*, Naoya Matsumoto, Eizo Tachibana, Koji Oiwa, Makoto Ichikawa, Kazumiki Nomoto, Hironori Haruta, Ken Arima and Atsushi Hirayama
  
  Background: In non-valvular atrial fibrillation (NVAF) patients with coronary artery disease (CAD), using antiplatelet drugs in addition to anticoagulants for stroke prevention may further increase the bleeding risk. Several guidelines have recommended an oral anticoagulant (OAC) monotherapy in patients with stable CAD one year after percutaneous coronary intervention (PCI). When considering early neointima healing of current 3rd generation drug-eluting stents (DESs), the duration of the de-escalation from a single antiplatelet drug plus an OAC to an OAC alone therapy can be shortened by less than one year after PCI. The data on the clinical acceptability of short durations for de-escalation to an edoxaban monotherapy in those patients are still lacking. Methods: A multicenter, prospective, randomized, open-label, parallel group study has been established to investigate the safety out.. View More»
  DOI: 10.35248/2167-0870.20.10.405

  Abstract HTML PDF